873197-15-0

Basic information

• Product Name: Glycine, N-[(1S)-2-hydroxy-1-methylethyl]-N-(phenylmethyl)-, 1,1-dimethylethyl ester
• CAS NO: 873197-15-0
• Molecular Formula: C16H25NO3
• Molecular Weight: 279.379
• Mol File: 873197-15-0.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Glycine, N-[(1S)-2-hydroxy-1-methylethyl]-N-(phenylmethyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Glycine, N-[(1S)-2-hydroxy-1-methylethyl]-N-(phenylmethyl)-, 1,1-dimethylethyl ester(873197-15-0)
• EPA Substance Registry System: Glycine, N-[(1S)-2-hydroxy-1-methylethyl]-N-(phenylmethyl)-, 1,1-dimethylethyl ester(873197-15-0)

Safety Data

• Hazardous Substances Data: 873197-15-0(Hazardous Substances Data)

Upstream product

• 100-52-7 benzaldehyde 
• 65943-49-9 (S)-2-{[1-Phenyl-meth-(E)-ylidene]-amino}-propan-1-ol 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 6940-80-3 (S)-N-benzylalaninol 

Downstream Products

• 1263774-30-6 [benzyl-(2-chloropropyl)-amino]acetic acid tert-butyl ester 
• 1263774-31-7 1-benzyl-3-methylazetidine-2-carboxylic acid tert-butyl ester 
• 1263774-35-1 2-(2-benzylaminoethyl)-3-methylazetidine-1,2-dicarboxylic acid di-tert-butyl ester 
• 873197-16-1 (2E,4S)-4-(benzyl-tert-butoxycarbonylmethyl-amino)-pent-2-enoic acid ethyl ester 
• 888494-42-6 (S)-2-[((2R,3S)-1-Benzyl-3-methyl-azetidine-2-carbonyl)-amino]-propionic acid methyl ester 
• 888494-37-9 t-butyl (2R,3S)-1-benzyl-3-methylazetidine-2-carboxylate 
• 929562-83-4 (2R,3S)-1-Benzyl-3-methyl-azetidine-2-carboxylic acid 
• 888494-24-4 tert-butyl (R)-N-benzyl-N-(2-chloropropyl)glycinate 

Relevant articles and documents

PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND CO-CRYSTALS THEREOF

The present invention relates to processes for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives which are useful as a Janus kinase (JAK) inhibitor, co-crystals thereof, processes for preparing the co-crystals, and processes for purifying 7H-pyrrolo[2,3-d]pyrimidine derivatives by employing the co-crystals. The present invention provides, for example, a process for preparing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile by employing a co-crystal of 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile with 3,5-dimethylpyrazole.

PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF

The present invention provides processes for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives, which are useful as a Janus kinase (JAK) inhibitor, intermediates thereof, and processes for preparing the intermediates. The present invention provides processes for preparing 3-[(3S, 4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile using salts of (3S,4R)-1-benzyl-3-methyl-1,6-diazaspiro[3.4]octane with organic acids.

CRYSTALLINE FORMS OF A JANUS KINASE INHIBITOR

The present invention relates to crystalline forms of the Janus kinase (JAK) inhibitor 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (Compound A), as well as, compositions thereof, methods of their preparation, methods of use thereof, and methods of quantitation.